Introduction {#S1}
============

Depression has been identified as the leading cause of disability worldwide, affecting approximately 300 million people globally ([@B99]; [@B35]). While antidepressants are still the standard treatment for depression, a debate regarding their efficacy has been emerging in recent years ([@B21]; [@B65]). A recent meta-analysis suggests only minor benefits compared to placebo treatments ([@B18]). Importantly, taking antidepressants seems to increase suicidality and all-cause mortality ([@B4]; [@B58]). Due to these obvious limitations of pharmacotherapy, alternative and safer treatment options are considered worthwhile. Importantly, the high recurrence rates among those affected by this debilitating disease indicate the need to complement conventional therapeutic approaches to improve depression prognosis ([@B11]).

Of note, autonomic functioning is shifted toward increased sympathetic activity in depression ([@B44]; [@B77]). Importantly, autonomic activity can be reliably and non-invasively assessed through heart rate variability (HRV), which refers to the fluctuation of subsequent beat-to-beat intervals of the heart rate, with mathematical analysis of HRV permitting inferences onto the underlying vagal modulations ([@B8]). HRV can be assessed in time-domain and frequency-domain measures ([@B79]). A sensitive indicator of vagally mediated HRV is the respiratory sinus arrhythmia (RSA), which reflects the concomitant increase in heart rate with inspiration and decrease with expiration, with the exact phase relationship between respiration and heart rate depending on the breathing frequency ([@B8]; [@B95]). Additionally, the root mean square of successive differences between normal heartbeats (RMSSD) is an established marker of vagally mediated HRV (vmHRV; [@B78]). Noteworthily, a recent meta-analysis shows attenuated vagal functioning in depressed individuals, manifesting in decreased heart rate variability, including vmHRV ([@B42]).

The neurovisceral integration model (NIM), first postulated by [@B90], provides a framework for a possible explanation regarding the link between depression and HRV. The NIM proposes that the regulation of affect, attention, and autonomic activity shares neural circuits, and therefore, vmHRV could index the efficacy of central--peripheral neural feedback loops ([@B91]). Importantly, the prefrontal cortex, central to executive functions, is considered as a major effector regarding autonomic functioning, exhibiting top-down inhibition on sympathetic activity ([@B91]). Thus, dysfunctional cognitions and emotions, respectively, could trigger the release of the prefrontal vagal brake, manifesting in decreased vmHRV ([@B91]; [@B88]). Accordingly, perseverative cognition like rumination is associated with attenuated vmHRV ([@B27]; [@B66]).

Importantly, enhancing HRV is hypothesized to increase cerebral oscillations, supposedly strengthening functional connectivity in brain areas relevant to emotion regulation, including prefrontal areas, which in return should improve mental well-being ([@B59]). Hence, increasing HRV via heart rate variability biofeedback (HRVBF) could constitute an alternative treatment for alleviating depressive symptoms. HRVBF is based on the phenomenon of maximum RSA amplification occurring at a specific respiratory frequency, which on average is approximately 5.5 (0.09 Hz) breaths per minute ([@B95]; [@B50]). Due to the cardiovascular resonance in response to this specific respiratory pattern, it has also been labeled resonant breathing ([@B96]). HRVBF supposedly amplifies autonomic reflexes, like the baroreflex, ultimately enhancing autonomic functioning, which eventually increases HRV ([@B95]; [@B50]; [@B48]). Noteworthily, breathing at such a slow rate (i.e., 0.09 Hz) shifts the RSA from the high-frequency (HF; 0.15--0.4 Hz) to the low-frequency (LF; 0.04--0.15 Hz) domain of HRV, which seems primarily vagally mediated ([@B50]; [@B45]).

Importantly, several studies have shown benefits of HRVBF on depression recovery and HRV in clinical depression ([@B36]; [@B87]; [@B30]; [@B13]; [@B54]). Although compelling, small sample sizes and lack of control groups in previous research limit interpretation and long-term outcomes of HRVBF have not been evaluated yet. Thus, the present work aims to expand prior research by evaluating for the first time the short- and long-term efficacy of HRVBF in individuals undergoing inpatient psychiatric rehabilitation. Importantly, the main intent of this study was to assess the general feasibility of HRVBF to improve depressive symptoms in patients already receiving a highly comprehensive treatment program. Since aiming at elucidating HRVBF's antidepressant efficacy on a more global level and in stationary psychiatric rehabilitation *per se*, patients with diagnoses other than depression were included.

Since inpatients are exposed to the same environmental factors during the 6-week in-clinic rehabilitation period, this provides an excellent context to investigate HRVBF's efficacy, especially as HRV seems sensitive to external influences like diet, exercise, and even air quality ([@B52]; [@B29]; [@B70]; [@B41]; [@B101]). Therefore, any HRV or depression differences occurring between the intervention group (IG) and the control group (CG) are likely due to HRVBF.

Based on the proposed benefits of HRVBF on depression recovery and autonomic functioning, we hypothesized that inpatient psychiatric rehabilitation supplemented by HRVBF will yield greater improvements in depressive symptoms and HRV than the standard treatment alone. Specifically, we expected that practicing HRVBF enhances vagal and baroreflex functioning, which should result in increased RMSSD, HF-HRV, and LF-HRV, respectively. Finally, the cumulative effect of increased vagal activity as well as improved baroreflex should manifest in improved overall variability and therefore increased SDNN. On an exploratory basis, we also evaluated whether HRVBF during rehabilitation affects 12-month recovery from depressive symptoms.

Materials and Methods {#S2}
=====================

Ethics Statement {#S2.SS1}
----------------

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional committees on human experimentation and with the Helsinki Declaration of 1975, as revised in 2013. This study was approved by the institutional ethics committee (GZ. 39/43/63 ex 2017/18). From all participants, oral and written informed consent was obtained.

Participants and Design {#S2.SS2}
-----------------------

Participants were recruited from a local inpatient psychiatric rehabilitation clinic, where they stay on average for 42 days. Patients taking antidepressants, anxiolytics, and other medication like anti-hypertensives or supplements, respectively, were included only if intake had been started at least 3 months prior study admission. The sampling protocol is shown in [Figure 1](#F1){ref-type="fig"}. Patients diagnosed with a substance-use disorder were excluded. Initially, 48 participants were randomly assigned to the intervention group (IG) and 44 participants to the control group (CG). Final sample size was reduced due to dropouts (IG = 8; CG = 5), diagnosed substance-use disorder (IG = 3; CG = 2), acute illness at post-assessment (IG = 1), severe side effects due to new medication (IG = 1), missing items in the BDI-II (IG = 1; CG = 3), artifacts in the electrocardiogram (ECG; IG = 1), and missing ECG assessments (CG = 2). Thus, the depression pre--post analyses included 68 participants (IG = 34; CG = 34) aged 26--66 (*M* = 48.7; *SD* = 9.4; [Table 1](#T1){ref-type="table"}). Pre--post data for HRV were available from 69 participants (see [Table 1](#T1){ref-type="table"}). The 12-month follow-up questionnaires were returned by 30 participants (IG = 14; CG = 16).

![Study design. *N* = 92 in-patients enrolled in the study and were randomly assigned to the intervention (IG) or control group (CG). Due to dropouts, missing items in the BDI-II, side effects from medication, illness, artifacts in the ECG, and missing assessments, the final sample size was reduced to 68 for the depression pre--post and to 69 for the HRV pre--post analyses, respectively. Overall, 30 participants (IG = 14; CG = 16) returned the follow-up questionnaires.](fnins-14-00738-g001){#F1}

###### 

Demographic information for the BDI-II and HRV pre--post analyses, between groups.

                                                                       **BDI-II**                 **HRV**                                
  -------------------------------------------------------------------- ------------ ------------- --------- ------------- -------------- -------
  Age in years (*M*, *SD*)                                             48.5 (8.2)   48.9 (10.6)   0.858     49.03 (7.7)   49.43 (10.4)   0.857
  Female sex (%)                                                       67.6         61.8          0.612     64.7          60.0           0.687
  Body mass index (*M*, *SD*)                                          25.6 (4.9)   27.9 (6.6)    0.105     25.7 (4.9)    27.7 (6.6)     0.165
  **Primary psychiatric diagnosis ICD-10 (%)**                                                                                           
  Schizophrenia and schizotypal and delusional disorders F20--29 (%)   0.0          5.9           0.151     0.0           8.6            0.081
  Affective disorders F30--39 (%)                                      76.5         73.5          0.779     76.5          71.4           0.633
  Neurotic, stress-related, and somatoform disorders F40--48 (%)       23.5         20.6          0.770     23.5          20.0           0.722
  Psychiatric comorbidity (%)                                          35.3         32.4          0.798     32.4          37.1           0.676
  Burnout symptoms Z73.0 (%)                                           20.6         14.7          0.525     17.6          14.3           0.703
  Psychotropics (%)                                                    85.3         91.2          0.452     85.3          88.6           0.686
  Psychotropics *N* (*M*, *SD*)                                        2.9 (1.9)    2.8 (1.5)     0.945     3.0 (2.0)     2.7 (1.5)      0.507
  Antidepressants (%)                                                  85.3         82.4          0.742     85.3          80.0           0.562
  Antidepressants *N* (*M*, *SD*)                                      1.8 (1.1)    1.8 (1.1)     0.914     1.9 (1.2)     1.7 (1.2)      0.563
  SSRI (%)                                                             64.7         79.4          0.177     64.7          71.4           0.549
  SNRI (%)                                                             38.2         17.6          0.059     41.2          17.1           0.028
  NaSSA (%)                                                            11.8         17.6          0.493     14.7          11.4           0.686
  Tricyclic (%)                                                        5.9          0.0           0.151     5.9           0.0            0.145
  Neuroleptics (%)                                                     20.6         23.5          0.770     23.5          25.7           0.833
  Atypical neuroleptics (%)                                            26.5         5.9           0.021     23.5          8.6            0.090
  Antiepileptics (%)                                                   5.9          26.5          0.021     5.9           28.6           0.013
  Anxiolytics (%)                                                      23.5         29.4          0.582     26.5          28.6           0.845
  Anxiolytics *N* (*M*, *SD*)                                          0.3 (0.5)    0.3 (0.5)     0.804     0.3 (0.5)     0.3 (0.5)      0.944
  Somatic comorbidity (%)                                              55.9         55.9          1.00      55.9          60.0           0.729
  CVD (%)                                                              17.6         17.6          1.00      17.6          20.0           0.803
  Chronic pain (%)                                                     11.8         17.6          0.493     11.8          17.1           0.526
  Respiratory disease (%)                                              8.8          5.9           0.642     8.8           5.7            0.618
  Anti-hypertensives (%)                                               26.5         23.5          0.779     29.4          25.7           0.731
  Supplements (%)                                                      29.4         26.5          0.787     29.4          28.6           0.939
  Vitamin D^3^ (%)                                                     11.8         20.6          0.349     11.8          20.0           0.375
  Probiotics (%)                                                       0.0          2.9           0.314     0.0           2.9            0.321
  Other (%)                                                            2.9          2.9           1.00      2.9           2.9            0.983
  **Behavioral data**                                                                                                                    
  Nicotine (%)                                                         32.4         48.5          0.178     33.3          47.1           0.252
  Alcohol (%)                                                          41.2         51.5          0.396     44.1          47.1           0.808
  Aerobic training (%)                                                 84.8         75.0          0.321     84.4          78.8           0.562
  Weekly aerobic training (*M*, *SD*)                                  230 (192)    160 (152)     0.114     230 (195)     171 (150)      0.182
  Strength (%)                                                         6.1          6.5           0.949     6.3           12.5           0.391
  Weekly strength (*M*, *SD*)                                          0.2 (0.7)    0.1 (0.6)     0.618     0.2 (0.7)     0.2 (0.8)      0.840
  In-clinic breathing training (%)                                     0.0          20.6          0.005     0.0           20.0           0.006

BDI-II, demographics between groups for depression pre--post comparisons; HRV, demographics between groups for HRV pre--post comparisons; variables tested by chi-square tests and by t-tests. CVD, cardiovascular disease. Aerobic training, total number and percentage of participants practicing aerobic exercise regularly. Weekly aerobic training, mean weekly volume of aerobic exercise in minutes. Strength, total number and percentage of participants practicing strength training regularly. Weekly strength, mean frequency of weekly strength sessions. N, total number. %, percentage. M, mean. SD, standard deviation

.

A 2 × 2 pre--post design was applied with group (IG vs. CG) as between-subject factor, time (pre--post; post-follow-up) as within-subject factor, and depression as well as various HRV measures as dependent variables. The IG practiced HRVBF in addition to the standard treatment. The CG received standard treatment only, provided with the opportunity to receive a brief HRVBF training after the study.

Procedure {#S2.SS3}
---------

On admission day, inpatients received an overview of the study and were assured about the confidentiality, anonymity, and possibility to withdraw from the study without negative consequences. They completed psychometric testing and two separate short-term HRV recordings, prior and after the 5-week intervention phase. After completing the baseline assessments, participants were randomly assigned to the IG or the CG, respectively ([Figure 1](#F1){ref-type="fig"}). After post-assessment, a 12-month follow-up regarding depressive symptoms was conducted in written form. During the follow-up period, no further support was provided.

Measures {#S2.SS4}
--------

### Demographics and Confounders {#S2.SS4.SSS1}

Participants filled out questionnaires regarding demographic/control variables at study entry. At admission, diagnoses and medication including supplement intake were obtained from the patient documentations. Medications and supplements were also assessed from the demographic/control questionnaires to record potential unregistered intake. Supplements were assessed, since various substances like vitamin D^3^ or probiotics seem to have mood-altering effects ([@B82]; [@B60]; [@B75]; [@B63]). Additionally, the care report of every participant was reviewed to control for changes in medication, occurring illness and extraordinary incidents.

Primary Outcomes {#S2.SS5}
----------------

### Depressive Symptoms {#S2.SS5.SSS1}

Depression severity was assessed with the Beck--Depression Inventory II (BDI-II) ([@B7]), which seems particularly sensitive to detect changes among psychiatric patients ([@B97]). The BDI-II consists of 21 items and is a self-report measure, assessing cognitive, affective, and neurovegetative symptoms of depression ([@B7]; [@B89]). In addition to an overall depression score, BDI-II distinguishes between a cognitive and somatic--affective subscale ([@B33]). Cronbach's alphas for the BDI-II overall score and the cognitive and somatic--affective subscales were 0.95, 0.91, and 0.92 at baseline; 0.95, 0.90, and 0.93 at post-assessment; and 0.95, 0.91, and 0.92 at follow-up, respectively, indicating high internal consistency ([@B67]).

Heart Rate Variability {#S2.SS6}
----------------------

### HRV Data Analysis {#S2.SS6.SSS1}

Heart rate variability was acquired by means of the "HRV Scanner," a one-channel ECG with a sampling rate of 500 Hz (BioSign GmbH, D-85570, Ottenhofen, Germany). The signal was obtained from two limb clamps, placed at participants' wrists. Data analysis was performed with the HRV-Scanner Software (BioSign GmbH, D-85570, Ottenhofen, Germany). Participants completed a 3-min short-term electrocardiogram (ECG), from which time-domain and frequency-domain measures were assessed. The ECG signal was automatically controlled for artifacts by the HRV-Scanner software, and only data containing less than five percent of artifacts were included for further analyses. Additionally, the ECG was visually controlled by two experienced examiners. One participant from the IG was excluded due to excessive artifacts (baseline: 5.04%; post-assessment: 8.65%). Of note, both groups showed similar mean artifact ratios at baseline (IG: *M* = 0.16, *SD* = 0.55; CG: *M* = 0.09, *SD* = 0.28) and post-assessment (IG: *M* = 0.15, *SD* = 0.77; CG: *M* = 0.04, *SD* = 0.25).

### HRV Measures {#S2.SS6.SSS2}

Heart rate variability parameters in the time domain encompass heart rate (HR), root mean square of successive differences (RMSSD), and standard deviation of RR intervals (SDNN). RMSSD is considered as a cardinal marker of parasympathetic activity and SDNN a global measure of all autonomic influences on HRV ([@B94]; [@B80]). Frequency-domain analysis classifies HRV into low (LF; 0.04--0.15 Hz) and high frequencies (HF; 0.15--0.4 Hz), expressed as ms^2^. HF power primarily reflects parasympathetic (i.e., vagal) activity ([@B8]). Although regarded as a marker of cardiac sympathetic control ([@B8]), a major vagal influence on LF power is proposed ([@B9]; [@B72]). Of note, during resting conditions, LF-HRV seems predominantly influenced by baroreflex and vagal activity, with only minor sympathetic contributions, compared to ambulatory settings, where sympathetic efference could be more dominant ([@B82]). Accordingly, [@B45] showed that increases in LF power due to slow breathing were predominantly vagally mediated.

We analyzed HR, SDNN, RMSSD, HF, and LF from the 3-min ECG recordings. Additionally, as an indicator of RSA the grade of rhythmization (GR) was calculated, which aims to quantify HRVBF success. This index integrates fluctuations of LF-HRV and HF-HRV. Specifically, changes in LF and HF are weighted against each other, with HF assigned a higher weight, thus quantifying the ratio of peak amplitude power compared to the remaining signals in the spectral analysis. This is due to the well-known phenomenon, that during states of enhanced cardiorespiratory coherence, an elevated peak and a narrower distribution of power can be observed in the spectrogram, shifting from HF to LF frequency. Therefore, GR increments correspond to an increase in the peak amplitude power, including a higher signal density centered around the peak and less power within the remaining frequencies, indicating a high RSA state. On the contrary a distribution of the power across a wider frequency range and a lower power peak, respectively, should indicate a lower GR and therefore a low RSA state. Hence, the GR aims at describing the quantity (i.e., height of amplitude) and quality of the RSA (i.e., presence of non-respiratory influences on the RSA), indicating the degree of cardiorespiratory coherence (e.g., [@B23]). It should be noted, though, that the GR is of explorative nature, since published validation studies are lacking. Frequency-domain HRV parameters were analyzed applying fast-Fourier transformation.

At the day of testing, participants were instructed to abstain from alcohol, nicotine, and exercise until HRV measurements were completed. Individuals were also instructed to fast at least 2 h prior to their appointments, as food intake potentially influences HRV ([@B31]; [@B56]; [@B20]; [@B74]; [@B41]). Due to circadian HRV fluctuations, participants' pre--post measurements were taken within the same 3 h of the day ([@B10]). The ECG was taken in a supine position after participants had rested for 10 min. Pre--post ECG measurements were conducted in the same climatized room.

### Breathing Frequency {#S2.SS6.SSS3}

Resting breathing frequency was analyzed pre- and post-intervention from the ECG. The HRV Scanner Software analyzes respiratory rate from the ECG signal, which is highly correlated with the actual breathing rate ([@B76]). Thus, ECG-derived breathing frequency has been suggested as an accurate measure of respiration ([@B92]).

Secondary Outcomes {#S2.SS7}
------------------

### HRVBF Training Compliance {#S2.SS7.SSS1}

We assessed three compliance measures. First, we documented participants' number of attended group trainings, and second, self-practice frequency was analyzed from the portable HRVBF devices. Third, an overall compliance score was calculated adding up group and self-practice frequencies.

### HRVBF Training Performance {#S2.SS7.SSS2}

To measure participants' HRVBF training performance, we assessed the relative grade of rhythmization (relGR). The relGR describes the mean achieved percentage of the set target GR (i.e., RSA amplitude required to receive a perfect feedback) during HRVBF sessions. Thus, the relGR objectifies the difficulty of the HRVBF while simultaneously measuring training success. For example, a relGR of 76 corresponds to producing on average 76% of the set target GR, while a relGR of 108 equals a mean GR, 108% of the target GR. Hence, the relGR can exceed 100% if the achieved values are higher than the set target GR, thus indicating superior performance. Additionally, respiratory rates were estimated from the biofeedback data, calculating the power peak in the frequency domains ([@B37]).

### Technical Details HRVBF {#S2.SS7.SSS3}

Heart rate variability biofeedback was delivered through a portable device named Qiu (BioSign GmbH, D-85570, Ottenhofen, Germany), which allowed participants to practice HRVBF at any time. The sphere-shaped device is battery-powered, has the size of a tennis ball, and measures heart rate by an optical sensor (i.e., photoplethysmography) at the palm, second digit, or thumb. Alternatively, an ear clip can be used to sense pulse rate. The Qiu provides the option to guide the practitioner's BF by moving blue LED lights, which can be set individually. The Qiu records date, time, and the RR intervals of every session. Once heart rate is detected, the luminescent upper half of the Qiu visualizes the current relGR through a continuous visual feedback, which ranges from dark red (i.e., low relGR) to bright green (i.e., high relGR). Accordingly, the optical feedback displays the degree to which practitioners achieve their target GR, which can be set individually, based on the participants' individual values. Importantly, the Qiu applies an algorithm controlling for error variance in the GR during the biofeedback, which ensures accuracy of the short feedback latency, necessary for the HRVBF.

In general, the HRVBF protocol used in this study differs from the original procedure (i.e., [@B49], [@B51]). The original protocol assesses the precise resonance frequency with a rather time intensive procedure as a basis for the actual HRVBF ([@B49], [@B51]). On the contrary, a 60-s deep breathing HRV test (DBT) is used to estimate the target HRV amplitude for the Qiu-HRVBF. In the DBT, participants breathe at 6 breaths per minute, which corresponds to the approximate resonance frequency, with inspiration and expiration lasting 5 s each, guided by a visual signal ([@B24]; [@B50]; [@B85]). Hence, instead of assessing the individual resonance frequency, the approximate maximum HRV amplitude is assessed from the DBT.

Precisely, the HRV Scanner software calculates the GR from the 60-s DBT, which is used by the Qiu as reference for the HRVBF. Importantly, Qiu's target GR is set higher than the actual maximum GR amplitude achieved in the DBT. Therefore, enough margin is provided to enable practitioners to achieve their actual peak HRV during the HRVBF practice. Thus, participants have to adapt their breathing pattern in response to the visual feedback to achieve their maximum HRV (i.e., GR) amplitude. Accordingly, practitioners determine their precise resonance frequency during every training session in order to achieve a positive feedback.

Treatments {#S2.SS8}
----------

### Standard Treatment (ST) {#S2.SS8.SSS1}

The ST consisted of 240 min of daily multifaceted therapies during the week and 80 min of therapy on Saturdays. These treatments included psychotherapy, psychoeducation, music therapy, physical and exercise therapy, and relaxation methods, including progressive muscle relaxation. Importantly, inpatients have to adhere to a strict treatment curriculum, which is equal for all inpatients, with non-adherence leading to early discharge. Hence, the IG and CG were comparable regarding treatment regiments independent of the HRVBF intervention. Of note, the clinic also provided breathing training by physical therapists, as additional individual therapy. Only the CG could participate in the in-clinic breathing training to avoid any confluent effects with the HRVBF on the study outcome.

### Details HRVBF Training Procedure {#S2.SS8.SSS2}

The IG received a 2-h introduction to the HRVBF, consisting of hierarchical steps: First, participants were taught nasal abdominal and pursed-lip breathing according to [@B49]. We emphasized nasal inspiration, as recent literature indicates improved entrainment of cerebral activity as compared to oral inspiration ([@B104]; [@B32]; [@B69]). In addition, switching from thoracic to abdominal breathing could improve vagal activation via slowly adapting stretch receptors during deep breathing ([@B64]). Pursed-lip breathing is supposed to improve breathing economy through decreasing air turbulences during exhalation and mechanically dilating the airways (e.g., [@B49]). Also, participants were instructed to focus the mind on the Dan Tian, a supposed "energy center" in the mind--body technique of Qi Gong, allegedly located three centimeters below the navel inside the belly ([@B16]). We integrated this idea as focusing on the Dan Tian while breathing seems to facilitate slow, deep breathing, which eventually is a prerequisite to successfully modulate HRV ([@B50]; [@B16]). Importantly, we disentangled this concept from its dogmatic valence and instructed participants to focus on the center of their abdomen to facilitate deep breathing. Second, participants were familiarized with the Qiu. Third, they were trained to use the taught techniques to modify their breathing and to adopt the latter according to the Qiu's visual feedback to optimize their HRV. Thus, the goal was to maximize the GR, rather than rigidly execute a specific technique. Fourth, participants received written instructions of the breathing techniques and details regarding Qiu usage, including self-practice.

The self-practice consisted of a 10-min HRVBF twice a day. Since participants had to attend the various standard treatments during the day, we recommended to do the first session in the morning and the second in the afternoon or evening, respectively. Participants were informed that they could train more HRVBF if they wanted to. Additionally, the IG was instructed to do three cycles of resonant breathing without the Qiu throughout the day, with each cycle lasting 10 breaths, trying to emulate the breathing pattern of the biofeedback-guided training. This additional practice aimed at familiarizing participants with the taught breathing techniques in order to facilitate HRVBF training. The HRVBF introduction was supplemented by one guided HRVBF session weekly (i.e., 5 sessions), consisting of approximately 35 min of HRVBF and 25 min for discussing any questions. In order to maintain training quality throughout the study period, the set target GR necessary to achieve a positive feedback was adjusted based on each individual's progression in performance.

Because groups shared the same environment (i.e., clinic) during the study, the IG was instructed not to communicate any details about the HRVBF with the CG to avoid potential transfer effects. Importantly, participants were stressed not to share their personal HRVBF device, since all training sessions are recorded and supposed to reflect each individual's performance and compliance, respectively.

Statistical Analyses {#S2.SS9}
--------------------

Data were analyzed with SPSS 25.0 software. To compare groups regarding demographic, medical, and behavioral variables, chi-square analyses and unpaired *t*-tests were conducted. Shapiro--Wilk tests were performed to analyze distributional characteristics ([@B83]). Accounting for skewed distributions, HRV measures were normalized using natural logarithmic transformation. Separate two-way mixed ANOVAs were performed, with group (IG, CG) as a between-subject factor and time (pre--post; post-follow-up) as a within-subject factor. Correlations were analyzed using Pearson's product--moment correlations. As a measure of effect size, partial eta-squared ($\eta_{\text{p}}^{2}$) is reported with small, medium, and large effects represented by the values 0.01, 0.06, and 0.14, respectively ([@B19]). Cohen's *d* was reported as effect size for *t*-tests with small, medium, and large effects, represented by the values 0.2, 0.5, and 0.8, respectively ([@B19]).

Results {#S3}
=======

Baseline Sample Characteristics {#S3.SS1}
-------------------------------

Regarding demographic and control variables, there were no significant baseline differences between the IG and CG. Both groups showed similar overall antidepressant intake and were slightly overweight with BMI values corresponding to early-stage obesity ([@B100]; see, [Table 1](#T1){ref-type="table"}). However, in the IG a tendency for higher SNRI intake, significantly higher use of atypical neuroleptics, and less frequent use of antiepileptics were observed (*p*s \< 0.05; [Table 1](#T1){ref-type="table"}).

Inpatients were diagnosed according to ICD-10 ([@B98]). The majority was diagnosed with affective disorders (ICD-10: F30--39), followed by neurotic, stress-related, and somatoform disorders and schizophrenia and schizotypal and delusional disorders (ICD-10: F20--29), respectively. However, no information regarding the precise number of episodes in case of recurrent depression was available. Within each group, approximately one third exhibited a comorbid (two or more) disorder with about a fifth exhibiting an additional burnout (Z73.0) diagnosis ([Table 1](#T1){ref-type="table"}).

Importantly, for HRV pre--post analyses, demographic characteristics including both, diagnoses (including specific ICD-10 diagnoses) and control variables, were similar to the depression pre--post analyses. Only the statistical tendency for higher SNRI intake in the IG was significant (*p* \< 0.05), while the less frequent use of atypical neuroleptics in the CG was non-significant (*p* \> 0.05; [Table 1](#T1){ref-type="table"}).

Of note, groups did not differ in severity of depressive symptoms (including subscales), diagnoses, or HRV variables at baseline (*p*s \> 0.05). Both groups showed moderate depression scores at baseline ([Table 2](#T2){ref-type="table"}).

###### 

Paired *t*-tests by group for depression and physiological measures at baseline and post-assessment.

                 **IG**                                            **CG**                                                                      
  -------------- ----------------- ------------------- ----------- -------- ------------------ ----------------- ----------- ------- --------- -------
  BDI-II total   21.59 (12.51)     9.18 (10.13)        7.565\*\*   1.30     19.97 (14.04)      12.5 (11.11)      4.621\*\*   0.79    4.602\*   0.065
  BDI-II cog     6.77 (5.85)       2.88 (3.95)         5.468\*\*   0.94     7.06 (6.38)        4.38 (4.56)       3.882\*\*   0.67    1.485     0.022
  BDI-II soma    13.74 (6.96)      5.82 (6.23)         7.566\*\*   1.30     11.88 (7.78)       7.44 (6.56)       4.846\*\*   0.83    6.230\*   0.086
  HR bpm         66.69 (11.11)     67.60 (11.60)       --0.593     0.10     68.50 (11.08)      69.37 (11.34)     --0.459     0.08    0.000     0.000
  BF cpm         13.15 (3.63)      9.81 (2.86)         5.039\*\*   0.86     13.52 (4.77)       12.42 (3.91)      2.039\*     0.35    6.928\*   0.094
  lnSDNN ms      3.38 (0.45)       3.42 (0.54)         --0.432     0.07     3.42 (.44)         3.42 (.53)        --0.024     0.004   0.105     0.002
  rSDNN ms       32.50 (15.18)     35.22 (21.55)                            33.66 (17.06)      34.58 (18.33)                                   
  lnRMSSD ms     3.10 (0.63)       3.00 (0.65)         1.003       0.17     2.92 (0.60)        2.93 (0.68)       --0.148     0.025   0.377     0.012
  rRMSSD ms      27.02 (18.54)     24.68 (18.96)                            22.52 (16.55)      24.04 (20.50)                                   
  lnLF ms^2^     5.25 (1.19)       5.86 (1.39)         −2.636\*    0.45     5.39 (1.29)        5.52 (1.40)       --0.696     0.12    2.468     0.036
  rLF ms^2^      340.77 (347.43)   1051.14 (2610.37)                        563.53 (1252.44)   549.93 (934.77)                                 
  lnHF ms^2^     5.25 (1.37)       4.85 (1.37)         1.630       0.28     4.66 (1.42)        4.79 (1.56)       --0.662     0.11    2.860     0.041
  rHF ms^2^      492.60 (814.66)   334.96 (587.88)                          322.70 (582.84)    380.42 (696.35)                                 
  lnGR           1.18 (0.73)       1.72 (0.96)         −3.547\*    0.61     1.40 (0.91)        1.54 (0.88)       --1.291     0.22    4.736\*   0.066
  rGR            4.09 (2.70)       9.05 (11.30)                             6.08 (6.53)        6.74 (6.74)                                     

Additional F-statistics for the interaction effects in the mixed ANOVAs. BDI-II total, Beck Depression Inventory II overall score; BDI-II cog, score in the cognitive subscale of the Beck Depression Inventory II; BDI-II soma, score in the somatic-affective subscale of the Beck Depression Inventory II; HR, heart rate; bpm, beats per minute; BF, breathing frequency; cpm, cycles per minute; ms, milliseconds; ms
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, milliseconds squared; ln, natural logarithmic normalization of the data; r, raw values; lnSDNN, logarithmized standard deviation of all normal-to-normal RR intervals; lnRMSSD, logarithmized root mean square of successive differences between normal heartbeats; lnLF, logarithmized low-frequency HRV; lnHF, logarithmized high-frequency HRV; lnGR, logarithmized grade of rhythmization; \*indicates p \< 0.05. \*\*indicates p \< 0.001.

The Efficacy of HRVBF on Improving Depressive Symptoms {#S3.SS2}
------------------------------------------------------

Depressive symptoms decreased over the course of the 5 weeks, as evidenced by a significant main effect of time in the mixed ANOVA with a large effect size \[*F*(1,66) = 74.510, *p* \< 0.001, $\eta_{\text{p}}^{2}$ = 0.530\]. Further, a moderating effect of group could be shown by a significant group × time interaction of medium effect size \[*F*(1,66) = 4.60, *p* = 0.036, $\eta_{\text{p}}^{2}$ = 0.065; [Figure 2](#F2){ref-type="fig"}\]. Paired *t*-tests showed significant decreases in the BDI-II score of 12.4 points in the IG \[*t*(33) = 7.57, *p* \< 0.001, *d* = 1.30\] and of 7.5 points in the CG \[*t*(33) = 4.62, *p* \< 0.001, *d* = 0.79; see [Table 2](#T2){ref-type="table"}\]. Main effects for time were also found for the cognitive \[*F*(1,66) = 43.92, *p* \< 0.001, $\eta_{\text{p}}^{2}$ = 0.400\] and somatic--affective subscales \[*F*(1,66) = 78.93, *p* \< 0.001, $\eta_{\text{p}}^{2}$ = 0.545\] with comparably large effects. A medium-sized moderating effect of group across time could be found for somatic--affective, \[*F*(1,66) = 6.23, *p* = 0.015, $\eta_{\text{p}}^{2}$ = 0.086\], but not for cognitive symptoms (*p* = 0.227, $\eta_{\text{p}}^{2}$ = 0.022). Paired *t*-tests revealed a significant decrease in the somatic--affective score of 7.9 points in the IG \[*t*(33) = 7.57, *p* \< 0.001, *d* = 1.30\] and 4.4 points in the CG \[*t*(33) = 4.85, *p* \< 0.001, *d* = 0.83; see [Table 2](#T2){ref-type="table"}\], respectively. No group differences in depression (including subscales) were found at post-assessment (*p*s \> 0.05).

![The IG, receiving the HRVBF in addition to the ST, showed a significant larger decrease in depressive symptoms over 5 weeks. BDI-II total, Beck Depression Inventory II overall score; HRVBF, heart rate variability biofeedback; ST, standard treatment. Error bars indicate ±1 SE.](fnins-14-00738-g002){#F2}

The Efficacy of HRVBF on Increasing Resting HRV {#S3.SS3}
-----------------------------------------------

For lnLF, a medium-sized main effect for time could be observed \[*F*(1,67) = 6.10, *p* = 0.016, $\eta_{\text{p}}^{2}$ = 0.083\], suggesting increasing values from pre- to post-assessment. Albeit no significant interaction for group × time was found (*p* = 0.121, $\eta_{\text{p}}^{2}$ = 0.036), *post hoc* paired *t*-tests showed significant increases in lnLF for the IG only \[*t*(33) = −2.64), *p* = 0.013, *d* = 0.45; see [Figure 3](#F3){ref-type="fig"}\] and no significant changes in the CG \[*t*(34) = −0.696), *p* = 0.491, *d* = 0.12; see [Table 2](#T2){ref-type="table"}\].

![While the CL group receiving the ST only did not show any changes in lnLF, the IG (HRVBF + ST) showed an increase in lnLF after the 5-week training period. HRVBF, heart rate variability biofeedback; ST, standard treatment. Error bars indicate ±1 SE.](fnins-14-00738-g003){#F3}

Regarding lnGR, a large-sized main effect for time \[*F*(1,67) = 13.42; *p* \< 0.001, $\eta_{\text{p}}^{2}$ = 0.167\] and a significant interaction for group × time of medium effect size were found \[*F*(1,67) = 4.74, *p* = 0.033, $\eta_{\text{p}}^{2}$ = 0.066; see [Figure 4](#F4){ref-type="fig"}\]. Paired *t*-tests evidenced a significant increase in lnGR for the IG only \[*t*(33) = −3.55, *p* = 0.001, *d* = 0.61; [Table 2](#T2){ref-type="table"}\]. No significant effects for the other HRV measures, heart rate included, were found (*p*s \> 0.05).

![While the IG (HRVBF + ST) exhibited significant increases in lnGR, the CG (ST only) did not show any substantial changes. HRVBF, heart rate variability biofeedback; ST, standard treatment. Error bars indicate ±1 SE.](fnins-14-00738-g004){#F4}

Effects of HRVBF on Resting Breathing Frequency {#S3.SS4}
-----------------------------------------------

Baseline breathing rates did not differ significantly between groups (*p* = 0.717, *d* = 0.09) and were within the normal range of human respiration (IG = 13.2 vs. CG = 13.5; [@B102]). Overall, resting breathing rate decreased, as evidenced by a large-sized main effect of time in the mixed ANOVA \[*F*(1,67) = 27.16, *p* \< 0.001, $\eta_{\text{p}}^{2}$ = 0.288\]. A significant medium-sized interaction of time × group illustrated a moderating effect of the HRVBF on resting respiratory rate \[*F*(1,67) = 6.928, *p* = 0.011, $\eta_{\text{p}}^{2}$ = 0.094\]. Paired *t*-tests showed large decreases in breathing frequency for the IG, from 13.2 to 9.8 breaths per minute \[*t*(33) = 5.04, *p* \< 0.001, *d* = 0.86\] and a small reduction from 13.5 to 12.4 for the CG \[*t*(34) = 2.04, *p* = 0.049, *d* = 0.35; [Table 2](#T2){ref-type="table"}\].

Adherence to HRVBF Training {#S3.SS5}
---------------------------

The mean number of attended group training sessions was 5.5 (*SD* = 0.6; range: 4--6), while the average self-practice frequency was 57 (*SD* = 26.6; range: 14--116) sessions, respectively. This corresponds to reaching a mean of 84.5% (*SD* = 34.5; range: 24.3--164.9) regarding overall target training frequency of 74 sessions (i.e., 68 self-practice sessions and 6 group trainings).

HRVBF Training Performance {#S3.SS6}
--------------------------

Mean relGR across sessions was 80.0%, which documents that throughout all sessions, participants achieved on average 80 percent of their individual maximum HRV peak. This indicates sufficient HRVBF training difficulty to induce potential autonomic adaptations (i.e., HRV increases). The average respiratory rate in the IG, calculated from the biofeedback data, was 5.5 (*SD* = 0.46; range: 4.7--6.8) breaths per minute, which is in line with the findings of previous research using more extensive assessment methods ([@B95]; [@B50]). Therefore, the GR seems to provide a feasible feedback signal to foster each individual's resonance frequency.

Exploratory Analyses {#S3.SS7}
--------------------

Overall depression scores were negatively associated with lnLF (*r* = −0.346, *p* = 0.006) and lnGR (*r* = −0.319, *p* = 0.011) at pre-assessment and at post-assessment (lnLF: *r* = −0.286, *p* = 0.020; lnGR: *r* = −0.315, *p* = 0.010). None of the evaluated compliance (i.e., practice frequency) and performance measures (i.e., relGR) were associated with changes in depression or HRV, respectively (*p*s \> 0.05). Also, the observed decreases in depressive symptoms including subscales were not associated with changes in any of the HRV parameters across the whole sample and within each group, respectively (*p*s \> 0.05).

12-Month Follow-Up of Depression Recovery {#S3.SS8}
-----------------------------------------

From thirty participants (IG = 14; CG = 16), depression follow-up data was available. No group differences in the control variables (*p*s \> 0.05) or depression severity (*p* = 0.511, *d* = 0.24) were found at baseline. A mixed ANOVA comparing depression severity between the IG and the CG from post-assessment to follow-up showed neither a significant main effect for time nor a time × group interaction (*p*s \> 0.05). However, the IG exhibited significantly lower depression scores of large effect size compared to the CG (*p* = 0.042, *d* = 0.79) at post-assessment. These additional antidepressive benefits due to HRVBF decreased during the 12-month post-discharge, illustrated by slightly smaller depression differences at follow-up (*p* = 0.195, *d* = 0.48). This effect seems to originate from a visible increase in depressive symptoms within the IG during the follow-up period (*p* = 0.118, *d* = 0.48). Importantly, none of the participants from the CG completing the follow-up took part in the brief HRVBF introduction at the end of the rehabilitation.

Discussion {#S4}
==========

This study evaluated whether HRVBF could enhance recovery of depressive symptoms and autonomic functioning in inpatients undergoing psychiatric rehabilitation. Moreover, a 12-month follow-up regarding depression trajectories was conducted, assessing the long-term sustainability of potential effects. Within 5 weeks, the IG exhibited a medium-sized, larger recovery in depressive symptoms than the CG, which appeared to be mainly driven by the comparably strong improvements in somatic--affective symptoms. However, these additional benefits gained during the treatment period vanished during the long-term follow-up. Noteworthily, toward the end of the treatment period, the IG showed medium- to large-sized amplification of LF-HRV as well as cardiorespiratory coherence (i.e., grade of rhythmization) at rest and a large reduction in resting breathing frequency, while no significant effects for RMSSD, SDNN, HF-HRV, or HR could be found. In comparison, no significant HRV changes could be observed in the CG, which, however, showed a small decrease in resting breathing rate.

Importantly, the present research complements the hitherto only randomized controlled trial by [@B13], who showed that HRVBF facilitated depression recovery and HRV in psychotherapy patients. These effects were larger as compared to our findings, which might be attributable to differences in sample characteristics. Of note, the comparably young sample in the Caldwell and Steffen study comprised women only, who seem to respond better to depression treatment and show larger autonomic adaptions due to interventions like exercise ([@B26]; [@B22]). Additionally, young individuals have shown larger HRV increases in response to interventions compared to middle-aged ones ([@B15]). Noteworthily, age seems to be an important factor regarding the efficacy of HRVBF on HRV, with young samples showing more reliable increases ([@B47]; [@B2]). Hence, the sample of the Caldwell and Steffen study could have been more sensitive to treatment effects regarding depression and HRV than those in the present research, who were approximately twice as old and included both sexes. It should also be mentioned that antidepressants seem to reduce HRV, with SNRIs and tricyclics having particularly unfavorable effects on vagal efferent cardiac control ([@B38]; [@B3]). However, SSRIs seem to attenuate vagal functioning as well, although depending on the SSRI class, with fluoxetine exhibiting the least adverse effects on HRV ([@B39]). In this regard, it is necessary to mention that only four participants included in the HRV analyses (IG = 3; CG = 1) were taking fluoxetine. However, this was supplemented with either antipsychotics, SNRIs, additional SSRI classes, or a combination of these medications. Additionally, antipsychotics have been shown to decrease HRV as well, with atypical neuroleptics seeming especially detrimental to autonomic functioning ([@B1]; [@B34]; [@B55]). Noteworthily, the IG exhibited a high intake of SNRIs and of atypical neuroleptics, which could explain why no improvements in RMSSD, HF-HRV, or SDNN could be observed. Therefore, we suggest that the advanced age and the density of pharmacological interventions may have attenuated an increase in autonomic functioning in the IG. It is also important to note that small samples tend to exaggerate effects ([@B12]). Thus, our findings may reflect HRVBF's efficacy more accurately than the comparably smaller study of [@B13].

Of note, this study provides first insights regarding the long-term sustainability of HRVBF-induced add-on benefits during inpatient psychiatric rehabilitation. Noteworthily, while groups showed no significant differences regarding the magnitude of depressive symptoms at baseline (*d* = 0.24), the IG compared to the CG exhibited significantly lower symptom severity of large effect size CG (*d* = 0.79) at the end of the rehabilitation period. Although these favorable antidepressive gains due to HRVBF became statistically non-significant at the 12-month follow-up assessment, these effects were still visible and of moderate size (*d* = 0.48). Seemingly, HRVBF generates unique psychophysiological benefits during the training phase, serving as additional resource even after the actual training period, which, however, appears to gradually vanish during a 12-month follow-up. Nevertheless, since we did not assess depressive symptoms and HRV at any time points between post-assessment and follow-up, no conclusions regarding psychophysiological trajectories can be drawn. Furthermore, slow-paced breathing practice during the follow-up period was not assessed, thus limiting the interpretation of the findings. However, it may be assumed that more intense training during stationary rehabilitation and/or continuing HRVBF after discharge may be necessary to maintain the initial benefits. Recently, [@B53] reported positive effects of a mobile-based HRVBF on autonomic balance, which could provide a useful tool to secure sustainability of the effects.

Nevertheless, the medium to large favorable effects of HRVBF shown in patients within 5 weeks of inpatient rehabilitation appear compelling and seemingly magnified the already large antidepressant effect of a well-validated, multidimensional treatment program (i.e., 25 h of weekly therapies). Moreover, the amplification of LF-HRV and GR, exclusively observed in the IG, could indicate enhanced autonomic efficacy. Importantly, under controlled resting conditions the LF-HRV seems predominantly influenced by baroreflex and vagal activity, with only minor sympathetic influences ([@B82]). Especially when breathing within the LF frequency range, LF-HRV reflects almost exclusively vagal efference ([@B45]). Since the IG exhibited a resting breathing rate at the upper end of the LF spectrum at post-assessment, the increases in LF-HRV within the IG could be considered of vagal origin. Regarding the GR, a cautious interpretation of this measure is imperative, as validation studies are lacking. It should be noted though that participants achieved resonance breathing during the Qiu biofeedback, thus indicating the utility of the GR as a marker of cardiorespiratory coherence. Taken together, we tentatively suggest that the IG exhibited improved vagal functioning. Certainly, further studies are needed to verify of falsify this hypothesis, especially since RMSSD, a sensitive marker of vmHRV, was not affected by the resonant breathing intervention ([@B82]). Still, HRVBF may exhibit unique therapeutic benefits independent of concurrent treatments. Hence, these findings emphasize the distinct effect of cultivating physiological coherence through resonance breathing on human psychophysiology. Of note, a study conducted in a similar setting found no additional antidepressive benefit of a mindfulness self-compassion training ([@B25]), despite showing antidepressant effects in a prior study ([@B62]). In general, breathing-based interventions seem to be of merit in improving depressive symptoms, potentially beyond conventional treatments approaches. For example, a study by [@B84] found that Sudarshan Kriya Yoga (SKY), a breathing-based meditation, induced large symptom improvements in depressed individuals resistant to antidepressant medication within 8 weeks. Of note, the largest reduction in depression occurred within the first 4 weeks, with small decreases during the subsequent half of the intervention period. In a further study, practicing SKY, which includes slow-paced breathing, resulted in enhanced vagal functioning in patients suffering from depression and/or anxiety, in addition to symptom reduction ([@B105]; [@B93]).

Recent research indicates that the benefits of paced breathing techniques on psychological well-being could originate from breathing-induced changes in brain activation patterns. During slow-paced breathing, slowly adapting stretch receptors in the lungs are recruited and in response amplify vagal afferent input to the nucleus tractus solitarius (NTS) in the brain stem ([@B14]; [@B46]). The NTS projects to cortical and subcortical areas of the brain, including prefrontal areas, the cingulate, the nucleus paraventricularis of the hypothalamus, and the amygdala, which show altered functioning in depressed individuals ([@B73]; [@B68]; [@B28]; [@B86]; [@B6]; [@B43]). Accordingly, cumulative evidence indicates that modulating respiratory patterns could entrain brain activity and, in turn, may generate a neurofunctional signature corresponding to emotional well-being ([@B103]; [@B64]). Hence, as hypothesized by [@B71], afferent vagal input, including slow-paced breathing, may aid in orchestrating emotional/psychological functioning via the cerebral susceptibility to upstream (i.e., afferent) vagal stimulation.

Indeed, these frequently suggested physiological pathways could be one origin of HRVBF's efficacy. However, since we did not find any associations between HRV changes and improvements in depressive symptoms, including subscales, psychological mechanisms may also contribute to its potency. For example, successfully modulating Qiu's visual feedback might foster self-efficacy, which seems decreased in depression ([@B5]; [@B57]). Of note, neither depression nor HRV trajectories were associated with mean relGR. Thus, the degree of participants' exposure to negative (i.e., red), neutral (i.e., orange), or positive (i.e., green) feedback during HRVBF had no distinct effect on the main outcomes. However, the sole experience of intentionally modulating the optical feedback or feelings of relaxation independent of the actual extent may have fostered self-efficacy.

To our knowledge, this study is among the first to objectively assess whether HRVBF self-practice frequency is linked to depression or HRV changes (e.g., [@B36]; [@B87]; [@B13]; [@B54]). Astoundingly, there were no significant associations. However, it could well be that participants generally engaged in slow-paced breathing practice independent of HRVBF, which unfortunately was not documented. Obviously, more research is necessary, targeting at the psychological and neurobiological mechanisms of the HRVBF effect. Nonetheless, considering no substantial HRV increases due to the standard treatment and the disturbed sympathetic--vagal balance in depression, our results suggest supplementing conventional therapies with HRVBF to specifically target autonomic dys/functioning (e.g., [@B40]; [@B44]; [@B17]; [@B77]). Moreover, the high level of practice adherence observed in the present study further supports the feasibility of HRVBF as adjunctive therapy in depressed individuals.

Strengths and Limitations {#S4.SS1}
-------------------------

This study has several strengths and limitations that should be mentioned. Overall, the highly standardized environment during inpatient psychiatric rehabilitation allowed us to control for various confounders, thus strengthening the validity of the findings. However, since this and prior studies were not placebo controlled, it has yet to be evaluated whether the promising antidepressive HRVBF effects are independent of a potential placebo effect. In addition, the CG did not receive a control intervention. Therefore, it could be that the additional attention due to the HRVBF group sessions may have fostered increased perceived social support and behavioral activation within the IG, thus contributing to the beneficial effects. Another positive aspect of this study is that we could objectively assess HRVBF training compliance. However, breathing practice independent of HRVBF was not documented, which may have diluted the non-findings regarding training adherence and outcome measures. Noteworthily, assessing depressive symptoms 1 year post-training constitutes a unique feature of this study as compared to previous research, thus elucidating for the first time potential long-term effects of HRVBF. On the contrary, neither HRV data at follow-up nor breathing practice during the 1-year period were obtained, thus limiting the interpretation of our results. Another factor potentially confounding the observed HRV increases is the relatively short ECG recording time of 3 min, as compared to the recommended 5 min ([@B8]). However, cumulative research indicates the reliability of ultra-short-term HRV recordings, suggesting the validity of our findings. For example, [@B81] propose that an ECG recording length of 180 s is sufficient to reliably calculate LF-HRV and HF-HRV, with 3-min recordings yielding almost identical results as 5-min measurements. Further, accurate measures of RMSSD and SDNN may be obtained from 2-min recordings ([@B61]).

Conclusion {#S5}
==========

The present research suggests additional benefits of HRVBF on the recovery of depressive symptoms and autonomic functioning in psychiatric rehabilitation inpatients. Thus, these findings argue for the value of HRVBF as adjunctive therapy during diverse treatment contexts, since it seemingly improves the therapeutic outcome regardless of concurrent treatment diversity and diagnosis. Importantly, the observed incremental effects could serve as resource after the training period and post-discharge, respectively. However, since the observed long-term trends did not reach significance, adequately powered follow-up studies are warranted to confirm this hypothesis and to examine ways to preserve initial therapeutic gains. Nevertheless, our findings support the implementation of HRVBF as additional intervention to foster the recovery of depressive symptoms, especially since it could provide add on-benefits, including enhanced autonomic regulation, as compared to current standard therapies. Further research is needed to examine the robustness of these findings and to control for placebo effects.
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